学术论文:  | 
   1. Liu G, Zhang Z, Wu Y, Feng J,   Lan Y, Dong D, Liu Y, Yuan H, Tai G, Li S, Ni W. Anti-PD-L1 antibody reverses   the immune tolerance induced by multiple MUC1-MBP vaccine immunizations by increasing   the CD80/PD-L1 ratio, resulting in DC maturation, and decreasing Treg   activity in B16-MUC1 melanoma-bearing mice. Int Immunopharmacol. 2023 Aug; 121:110487.   doi: 10.1016/j.intimp.2023.110487. Epub 2023 Jun 24. PMID: 37364328. 2. Jie J, Liu G, Feng J, Huo D,   Wu Y, Yuan H, Tai G, Ni W. MF59 Promoted the Combination of CpG ODN1826 and   MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC   Maturation by Prolonging the Local Retention Time of Antigen and   Down-Regulating of IL-6/STAT3. Int J Mol Sci. 2022 Sep 17;23(18):10887. doi:   10.3390/ijms231810887. PMID: 36142800; PMCID: PMC9501507. 3. Liu Y, Zhang Z, Sang Q, Zhang   Y, Jiang M, Zhou H, Wang J, Zhang N, Wu X, Zhou J, Ni W, Yuan H, Tai G.   Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces   antigen-specific CTL responses through cDC1-mediated cross-priming mainly   regulated by type I IFN signaling in mice. Immunol Lett. 2022 May;245:38-50.   doi: 10.1016/j.imlet.2022.04.002. Epub 2022 Apr 9. PMID: 35405170. 4. Wang J, Liu Y, Ni W, Wu X,   Zhou J, Zhang Z, Zhou H, Zhang N, Jiang M, Sang Q, Yuan H, Tai G.   TRAF6-overexpressing dendritic cells loaded with MUC1 peptide enhance   anti-tumor activity in B16-MUC1 melanoma-bearing mice. Int Immunopharmacol.   2022 Jun;107:108667. doi: 10.1016/j.intimp.2022.108667. Epub 2022 Mar 4.   PMID: 35255300. 5. Zhang Z, Zhou H, Liu Y, Ren   J, Wang J, Sang Q, Lan Y, Wu Y, Yuan H, Ni W, Tai G. Anti-PD1 antibody   enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via   increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the   B16-MUC1 melanoma mouse model. Int Immunopharmacol. 2021 Dec;101(Pt   A):108173. doi: 10.1016/j.intimp.2021.108173. Epub 2021 Oct 1. PMID:   34607233.  |